SCHEMBL22236137

SCHEMBL22236137

COC(=O)c1cc2c(n(C)c1=O)-c1nc(Cl)c3ccccc3c1CC2C(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRG2 P18507 7/20 0.41
▸ GABRB3 P28472 7/20 0.41
▸ GABRA3 P34903 7/20 0.41
▸ GABRA1 P14867 5/20 0.41
▸ KDM4E B2RXH2 5/20 0.38
▸ GABRA2 P47869 5/20 0.37
▸ GABRA5 P31644 2/20 0.37
▸ BRD4 O60885 1/20 0.37
▸ GAA P10253 3/20 0.35
▸ ALDH1A1 P00352 4/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ USP2 O75604 1/20 0.35
▸ PKM P14618 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ TSHR P16473 1/20 0.34
▸ LMNA P02545 2/20 0.34
▸ HPGD P15428 2/20 0.34
▸ GLA P06280 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22235748 0.90 KDM4E (0.32) KDM4EALDH1A1MEN1KMT2AHPGD
SCHEMBL22235429 0.90 KDM4E (0.32) KDM4EALDH1A1MEN1KMT2AHPGD
SCHEMBL22235426 0.90 KDM4E (0.32) KDM4EALDH1A1MEN1KMT2AHPGD
SCHEMBL22235343 0.81 GABRA1 (0.35) GABRG2GABRB3GABRA3GABRA1KDM4E
SCHEMBL22235409 0.81 GABRA1 (0.35) GABRG2GABRB3GABRA3GABRA1KDM4E
SCHEMBL22235514 0.81 GABRA1 (0.35) GABRG2GABRB3GABRA3GABRA1KDM4E
SCHEMBL24357127 0.78 MAPK8 (0.37) KDM4EMEN1KMT2ATSHRLMNA
SCHEMBL24357361 0.70 ALDH1A1 (0.35) GABRG2GABRB3GABRA3GABRA1KDM4E
SCHEMBL22236138 0.70 — —
SCHEMBL22235398 0.70 PDK2 (0.35) GABRG2GABRB3GABRA3GABRA1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220125771-A1 SUBSTITUTED POLYCYCLIC CARBOXYLIC ACIDS, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2022-04-28 — — US disclosed
CN-113825756-A Substituted polycyclic carboxylic acids, analogs thereof, and methods of use thereof 爱彼特生物制药公司 2021-12-21 — — CN disclosed
EP-3911653-A1 SUBSTITUTED POLYCYCLIC CARBOXYLIC ACIDS, ANALOGUES THEREOF, AND METHODS USING SAME Arbutus Biopharma Corporation (CA) 2021-11-24 — — EP disclosed
WO-2020150366-A1 SUBSTITUTED POLYCYCLIC CARBOXYLIC ACIDS, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2020-07-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220125771-A1 SUBSTITUTED POLYCYCLIC CARBOXYLIC ACIDS, ANALOGUES THEREOF, AND METHODS USING SAME SLC10A1, NR1H4, HDGF GABRG2 2687/4885GABRB3 2399/4885GABRA3 1667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback